|
Evaluation of the possible association between higher than normal nuchal translucency with common mutations of SMN2 and PTPN11 genes in normal karyotype of pregnant women referred to Noor Comprehensive Genetics Center’s Clinic between 2019 and 2021
|
Raana Mahmoudi    , Maryam Eslami 1, Mahmoud Tavallaie2 |
1- Assistant Professor, Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran-Applied Biotechnology Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran , Drmaryam.eslami2020@gmail.com
2- Medical Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran |
|
|
Abstract: (601 Views) |
Background: Nuchal translucency (NT), the ultrasound transparency detected behind the fetal neck, is considered a marker in the first trimester. Excessive increase in this marker is associated with chromosomal and structural abnormalities, as well as congenital birth defects, especially cardiovascular abnormalities. Noonan Syndrome and Spinal muscular atrophy (SMA) are two common associated syndromes with autosomal dominant and recessive inheritance respectively. PTPN11 is the most common gene whose mutation leads to Noonan syndrome. SMN2 gene is a modulating gene and in case of mutation, it leads to a benign increase in NT. The purpose of this article was to determine the causes for increased nuchal translucency in fetuses with normal karyotype by studying mutations in SMN2 and the two common exon 3 and exon 13 of PTPN11.
Materials and methods: In this study, forty cases from Noor Genetics Clinics were entered. The cases were those who have both increased NT and normal karyotype. Amniotic fluid samples were acquired and DNA was extracted at the molecular laboratory. Then, genetic investigations were conducted using Real Time PCR and Sanger sequencing.
Results: The investigation discovered four cases with deletion in SMN2; which none presented SMA pathogenesis. In one sample, Noonan syndrome pathogenesis through mutation in exon 13 was observed, while no mutation in exon 3 was observed in any of the samples.
Conclusion: According to this study, it is suggested that molecular investigations, especially Noonan syndrome in fetuses with high NT level, should be included in the pregnancy screening program and diagnostic protocols in the society.
|
|
| Keywords: NT ultrasound, Noonan Syndrome, SMA, SMN, PTPN11 |
|
|
Full-Text [PDF 333 kb]
(258 Downloads)
|
Semi-pilot: Survey/Cross Sectional/Descriptive |
Subject:
Genetic
Received: 2022/09/12 | Accepted: 2023/02/12 | Published: 2023/10/2
|
|
|
|
|
|
|
| References |
1. Newey VR, Nassiri DK, Bhide A, Thilaganathan B. Nuchal translucency thickness measurement: repeatability using a virtual ultrasound scanner. Ultrasound Obstet Gynecol 2003;21:596-601.
2. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-6.
https://doi.org/10.1016/S0140-6736(97)11280-6
3. Krzyżanowski A, Kwiatek M, Gęca T, Stupak A, Kwaśniewska A. Modern Ultrasonography of the Umbilical Cord: Prenatal Diagnosis of Umbilical Cord Abnormalities and Assessement of Fetal Wellbeing. Med Sci Monit 2019;25:3170-80.
https://doi.org/10.12659/MSM.913762
4. Petersen OB, Smith E, Van Opstal D, Polak M, Knapen M, Diderich KEM, et al. Nuchal translucency of 3.0-3.4 mm an indication for NIPT or microarray? Cohort analysis and literature review. Acta Obstet Gynecol Scand 2020;99:765-74.
https://doi.org/10.1111/aogs.13877
5. Ali MM, Chasen ST, Norton ME. Testing for Noonan syndrome after increased nuchal translucency. Prenat Diagn 2017;37:750-3.
https://doi.org/10.1002/pd.5076
6. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381:333-42.
https://doi.org/10.1016/S0140-6736(12)61023-X
7. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007;39:70-4.
https://doi.org/10.1038/ng1926
8. Athota JP, Bhat M, Nampoothiri S, Gowrishankar K, Narayanachar SG, Puttamallesh V, et al. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations. BMC Med Genet 2020;21:50.
https://doi.org/10.1186/s12881-020-0986-5
9. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin 2015;33:831-46.
https://doi.org/10.1016/j.ncl.2015.07.004
10. Barone C, Bianca S. Further evidence of no association between spinal muscular atrophy and increased nuchal translucency. Fetal Diagn Ther 2013;33:65-8.
https://doi.org/10.1159/000343252
11. Pearn J. Classification of spinal muscular atrophies. Lancet 1980;1:919-22.
https://doi.org/10.1016/S0140-6736(80)90847-8
12. Westin M, Saltvedt S, Almström H, Grunewald C, Valentin L. By how much does increased nuchal translucency increase the risk of adverse pregnancy outcome in chromosomally normal fetuses? A study of 16,260 fetuses derived from an unselected pregnant population. Ultrasound Obstet Gynecol 2007;29:150-8.
https://doi.org/10.1002/uog.3905
13. Gezdirici A, Ekiz A, Güleç EY, Kaya B, Sezer S, Atış Aydın A. How necessary is to analyze PTPN11 gene in fetuses with first trimester cystic hygroma and normal karyotype? J Matern Fetal Neonatal Med. 2017;30:938-41.
https://doi.org/10.1080/14767058.2016.1191463
14. Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, Kikuchi A, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer. 2006;45:583-91.
https://doi.org/10.1002/gcc.20322
15. Parra J, Tizzano EF. Raising obstetricians' awareness of spinal muscular atrophy: towards early detection and reproductive planning. J Matern Fetal Neonatal Med. 2012;25:2555-8.
https://doi.org/10.3109/14767058.2012.703720
16. Lin Y, Wang, Chau MHK, Lou J, Zeng X, Liang Y, et al. Contribution of Pathogenic CNVs and Noonan Syndrome in Fetuses with Increased Nuchal Translucency and Persistently Increased Nuchal Fold Austin J Obstet Gynecol 2021; 8: 1174. [ DOI:10.1002/uog.124] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Mahmoudi R, Eslami M, Tavallaie M. Evaluation of the possible association between higher than normal nuchal translucency with common mutations of SMN2 and PTPN11 genes in normal karyotype of pregnant women referred to Noor Comprehensive Genetics Center’s Clinic between 2019 and 2021. MEDICAL SCIENCES 2023; 33 (3) :257-262 URL: http://tmuj.iautmu.ac.ir/article-1-1992-en.html
|
